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Summary Out of 130 ovarian cancer patients the DNA index of cells from ovarian carcinoma was studied in
56 cases in which cytospin preparations showed the presence of atypical cells. In 24 patients the population
had a diploid DNA index (1.0) and in the others the DNA index ranged from 1.2 to 2.0 (tetraploid). No
hypodiploid or hypertetraploid populations were detected. Repeated samples from the same patients did not
show any significant differences and primary culture did not alter the DNA index. In contrast, cell cycle
phase distribution differed greatly from sample to sample, as also the ratio between DNA diploid and DNA
aneuploid populations. Primary culture was successful in 57% of the tumours, with a higher percentage of
success in DNA aneuploid tumours. After primary culture the ratio between DNA aneuploid cells and DNA
diploid cells increased. In relation to the histological gradings of malignancy, DNA aneuploid cells clustered
in the highest grade of malignancy. The mean S-phase for tumours with a DNA index of 1.0 was 3.5 and
14.1% for those with DNA index >1. Ovarian carcinomas show a large difference in DNA index between
patients even after primary culture.
Flow cytometric measurement of DNA content in
human cancer cells is becoming a procedure for
defining the DNA index and cell cycle distribution
of the cell population. This may have several
practical applications including prognostic value
(Herman et al., 1979; Laerum & Farsund, 1981;
Linden, 1982) assessment of sensitivity to chemo-
therapy (Laerum & Farsund, 1981; Linden, 1982;
Barlogie et al., 1983; Buchner et al., 1980) and
the follow up of cultured tumours (Maiolo et al.,
1982; Friedlander et al., 1983).
We applied the cytofluorometric technique to the
study of human ovarian tumours with the following
aims: (i) to describe the DNA index in ovarian
cancers, (ii) to establish the extent to which the
DNA index is modified by growing cancer cells in
vitro, (iii) to correlate the DNA index with the
cytological degree ofmalignancy.
Materials and methods
Biopsy material for analysis was obtained from
primary surgery, from second look laparotomy,
pleural effusion or from ascitic fluid after
paracentesis. All patients were classified by FIGO
staging as III and IV and by histologically
confirmed diagnosis as serous, mucinous, undifferen-
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tiated, mixed or endometroid ovarian carcinoma
(Young et al., 1982). Histological grading of
tumours was evaluated in terms of well differen-
tiated (grade 1), moderately differentiated (grade 2)
and poorly differentiated (grade 3) (Long &
Sommers, 1969) and according to Broders criteria
(Broders, 1926; Ozols etal., 1980). As cell suspensions
were also used for seeding primary cultures, single
cells were obtained from the biopsy material by a
sterile procedure.
Tumour biopsy specimens were collected in PBS
containing 100Uml-I penicillin and 100pgml-
streptomycin (GIBCO Europe, Glasgow, Scotland)
and rapidly processed in the laboratory a few hours
after collection. Tissue was divided up and
fragments were squashed on prestained slides (Test
Simpletsl, Boehringer, Mannheim GmbH, W.
Germany) to test for the presence of cells spilled
out from connective tissue and to confirm diagnosis
grossly. Soft tissue from which cells spilled out
easily was then disaggregated by treating 2mm
fragments with 0.25% tripsin 1:250 (Difco
Laboratories, Detroit, Michigan, USA) in PBS
without calcium and magnesium for 30min at 37°C
in a baffled flask on a magnetic stirrer.
Hard tumours from which few cells could be
spilled out were minced carefully into very small
fragments then treated for 1 h at 37°C with
collagenase type 1 (Sigma Chemical Company, St.
Louis, USA) dissolved 0.1-0.3% in medium 199
without serum. Cell suspensions were then washed
and resuspended in growth medium.
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Ascitic fluid was collected in heparinized bottles
and centrifuged at 200g for 10min to separate the
cellular phase. After resuspension in PBS a first
microscopy check was made. Suspensions
containing RBC and mononuclear cells were
separated by a discontinuous gradient of 100%
Ficoll-Hypaque (d= 1.077; MSL, Eurobio, Paris)
for 20min at 600g. The tumour cells in the upper
layer of the gradient were then freed of
macrophages by the adhesion method (Mantovani
et al., 1979).
When a large number of lymphocytes was
present, a second gradient of one 75% and one
100% Fycoll-Hypaque was made to separate cancer
cells from lymphocytes. After this step ascitic cells
were resuspended in growth medium.
At this stage viability was tested by the
erythrosine dye exclusion test in cell suspensions
from solid or ascitic samples. A cytospin
preparation of each sample was also made to check
the presence of different types of normal and
neoplastic cells before staining for flow cytometry.
Only suspensions positive for atypical elements and
with >70% viable cells were then seeded at 350,000
viable cellsml-1 in T25cm2 tissue culture flasks
(Sterilin-Flow Laboratories, Irvine, UK). Growth
medium 199 was supplemented with 15% foetal calf
serum, 2mM glutamine, 6% of MEM essential
aminoacid stock solution, 3% stock solution of
MEM vitamins (all purchased from Flow
Laboratories, Irvine, UK) and 20mM HEPES;
(Merck, Darmstadt, W. Germany). The pH was set
at 7.2 in air, with osmotic pressure kept at
285+10mosmol (Morasca et al., 1983). Successful
cultures gave monolayers in T-flasks and were used
for in vitro testing of sensitivity to anticancer
agents, when there were sufficient cells present in
suspension to run enough primary cultures.
The samples for flow cytometry were stained with
propidium iodide (PI) (Calbiochem Behring Co.,
USA) by adding 3ml of PI solution (50pgml-1 PI
in 0.1% sodium citrate containing 30p1 Nonidet
P 40 detergent (Sigma), and 30p1 RNAse
0.5mgml 1 (Calbiochem, Behring, Co., USA), to
200-300p1 of cell suspension at room temperature
for 30-45min (Vindel0v, 1977). Cells in culture
were washed three times with PBS and directly
stained with the same PI solution. In this way
nuclei were dislodged from the cells, adhering to
the plastic surface of the flask, and entered into
suspension without the cells having to be suspended
(Lau & Pardee, 1982). The suitability of the
preparation, the specificity of staining and the
absence of aggregates were checked by fluorescence
microscopy before the sample was run.
To determine the DNA index, human leucocytes
from freshly collected blood were used as standard.
Standard was run before and after the sample to
check for drifting of the laser output. Doublets
were <1% by morphological examination of the
tumour cell suspension. Leucocyte standards always
contained <0.8% of doublets.
Cytofluorometric analysis was performed using a
30L Cytofluorograph (Ortho Instruments, USA).
The fluorescence pulses were detected in a spectral
range between 580 and 750nm (to exclude the
overlapping region of excitation and emission
spectra or unbound PI), and integrated. The
coefficient of variation (CV) of the standard was
between 1.5-2.5% while in ovarian cancer cells the
CV of the GO/Gl peak was 3-4%. Routinely at
least 50,000-100,000 cells were measured at a flow
rate of less than 500 cellssec-1 (Erba et al., 1983).
Ploidy was expressed as DNA index, representing
the ratio between the G1 peak of ovarian cancer
cells and the peak of leucocytes (Barlogie et al.,
1983). The percentage of cells in the cell cycle
phases was calculated by the method of Baisch et
al. (1975) and the number of cells in each phase
was also calculated. The simulated randomization
test was used to study the relationship between
ploidy and the percentage of cells in the S phase
(Recchia & Rocchetti, 1982).
Results
Only 56 samples out of 130 could be studied by
flow cytometry on the basis of morphological
evidence of atypical cells in the suspensions. Among
these we found ten patients (1-10) presenting a
DNA distribution identical to normal human
leucocytes, with a DNA index of 1.0 and no cycling
cells. Despite the absence of cycling cells, in four of
these cases cells grew in vitro. In all these samples
atypical cells were present in cytospin preparations,
and only in two of them was the percentage of
atypical cells <5%. In two cases with 26 and 30%
of atypical cells, however, we were not successful in
growing cells in vitro.
DNA diploid cycling cells were found in 14
patients (11-24) (Table I); the proportion of cells in
S phase ranged from the threshold of detection
(0.2%) to 16.1%. In this group of DNA diploid
cells, the capacity to grow in vitro was low (35%).
Figure 1 shows a typical histogram (patient No.
14).
Non cycling cells were found in a few DNA
aneuploid tumours. Patients 25, 26 and 27 with
DNA indices of 1.2, 1.89 and 2.00 respectively, had
DNA distributions with no detectable cells in the S
and G2+M compartments. Two of these tumours
nevertheless grew in vitro. Figure 2 represents the
DNA histogram of patient No. 25.
Table II reports eighteen cases (28-45) in which
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Table I Fourteen cases of ovarian cancer with cycling DNA diploid tumour cellsa
Cell cycle phase %
aPatient Growth in
No. DNA index G1 S G2M culture Description"
11 1 94.4 0.6 5 - UN A
12 1 95.5 2.4 2 + SE A
13 1 94.1 4.2 1.7 - SE A
14 1 88 1.6 10.4 - MU P
15 1 92.5 3.1 4.4 Fibroblasts MX P
16 1 91.2 0.6 8.2 - EN P
17 1 90.4 4.3 5.3 - UN A
18 1 93.2 1.6 5.1 + SE A
19 1 96 0.2 3.8 - EN P
20 1 95.8 1.3 2.9 + SE A
21 1 87.7 7.1 5.2 - SE P
22 1 71.5 16.1 12.4 - SE OM
23 1 90.9 4.7 4.4 + SE A
24 1 93.9 2.3 3.8 + SE P
'DNA diploid Index=1.0.
The percentages of cells in G1, S and G2 +M phases of the cell cycle, success in culture, the histological
type and origin of cancer cells are indicated; bUN=Undifferentiated, SE= Serous, MU = Mucinous, MX
= Mixed, EN=Endometrioid, A=Ascitic fluid, P=Primary tumour, OM =Omental metastasis.
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Figue 1 DNA diploid index and cell cycle distri-
bution of patient No. 14. From left to right, the
first peak represents the GO/G1 peak of DNA diploid
cancer cells overlapping with human leucocytes; the
small second peak represents the tumour cells in
G2+M phase of the cell cycle; between GO/G1 and
G2 +M peaks are cells in S phase.
DNA diploid non-cycling and a DNA aneuploid
cycling population. In these cases the cells in S
phase ranged from 1.1 to 37.1% and 15 out of 18
of them gave primary cultures. Figure 3 shows a
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Figure 2 DNA aneuploid index of patient No. 25.
From left to right, the first peak represents the DNA
diploid cell in the tumour overlapping with human
leucocytes used as standard; the second peak
represents the DNA aneuploid cancer cells.
DNA histogram of one of these cases (patient
No. 36).
The last eleven patients (45-56) had tumours
with a complex DNA distribution suggesting the
n
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Table II Eighteen cases of ovarian cancer with cycling DNA aneuploid tumour cellsa
Cell cycle phase %
aPatient Growth in
No. DNA index G1 S G2M culture Descriptionb
28 1.48 97.2 1.4 1.4 - EN P
29 1.4 85.3 4.7 1 + SE PE
30 1.38 69.9 17.2 12.9 Fibroblasts SE PE
31 1.52 59.8 23.2 16.9 + SE P
32 1.60 68.5 24 7.5 + SE A
33 1.72 85.5 8.9 5.6 + SE P
34 1.74 83.2 9.2 7.6 + SE A
35 1.67 79.8 7.3 12.9 + SE A
36 1.72 78.6 8.4 13 + SE A
37 1.94 93.2 6.8 0 + SE P
38 1.27 93.3 1.1 5.6 - SE A
39 1.50 67.1 21.2 11.7 + SE A
40 1.87 60.2 30.8 9 + SE A
41 1.19 68 15 17 + SE A
42 1.72 54.7 37.1 8.2 + SE A
43 1.30 74.8 11.9 13.3 + SE A
44 1.35 69.9 17.1 15.8 + SE A
45 1.2 90 5.5 4.5 - EN P
aThe DNA index, cell cycle distribution, growth in culture, tumour histological type and origin of cancer
cells are reported; bEN=Endometrioid, SE=Serous, P=Primary tumour, PE=Pleural effusion, A=Ascitic
fluid.
extrapolate a cell cycle distribution because the
portion of DNA diploid cells in G2 +M phase
overlapped the S phase of DNA aneuploid cells.
DNA indices ranged from 1.39 to 1.89 and 7/11
samples grew in culture.
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Figure 3 DNA aneuploid index and cell cycle
distribution of patient No. 36. The left-hand peak
represents the GO/GI peak of DNA diploid cells
overlapping with human leukocytes; the right-hand
peak, the G1 peak of DNA aneuploid cancer cells with
cells in S and G2+M phases of the cell cycle.
presence of two cycling populations, as can be seen
from the DNA distribution of patient No. 48
(Figure 4). In these cases no attempt was made to
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Figure 4 DNA pattern of patient No. 48: two
different cycling cell populations are present, one DNA
diploid, the higher peak on the left, and one DNA
aneuploid, the second peak.DNA INDEX OF OVARIAN CANCERS 569
From a few patients it was possible to collect
several samples to check the stability of the DNA
index over time and from different lesions. Figure 5
illustrates the histograms of two patients: patient
No. 33 over a 4-month period had the DNA
aneuploid population stable on channel 85 while
the ratio of DNA diploid to DNA aneuploid cells
and cell cycle phase distribution differed markedly
from one sample to the next.
Pat. no. 33
A
70 140 210
Patient No. 44 was monitored over 6 months
with ten samples of ascitic fluid. The DNA index
remained stable in this case also. Figure 6 shows
one of the cases in which primary and metastatic
tumours revealed no difference in DNA index.
The DNA index and the cell cycle distribution
was studied before and after in vitro culture in 33
of the 56 cases studied (57%). Figure 7 reports four
samples of ascitic fluid from a single patient. The
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Figure 5 DNA pattern and cell cycle distribution of samples from two patients, from whom several samples
could be collected at different times.
Patient no. 33: samples A-B, D-H =ascitic fluid; C =Pleural effusion.
Patient no. 44: all samples=Ascitic fluid.570 E. ERBA et al.
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Figure 6 DNA pattern of ovarian cancer cells from
the same patient from different sites.
Patient No. 40=a=primary tumour
b =omental metastasis.
peak of DNA aneuploid cells remained constant
after culture, the DNA index varying by only 0.05.
This did not reach significance on the 33 pairs
analyzed by Wilcoxon's signed rank test. The
proportion of cells in different peaks shifted in
favour of DNA aneuploid cells and at the first
passage samples 1 and 4 had a similar distribution
of DNA aneuploid cycling cells.
The rate of DNA aneuploidy and proportion of
cells in S phase is reported in Table III for different
histological gradings. Despite the limited number of
cases there was a tendency for DNA aneuploidy to
cluster at grade 3 and Broders' 4/4. Populations
with a high mean proportion of cells in S also
Table III Correlation between histological gradings with
DNA aneuploidy and percentage of cells in S phase
No. of Mean percentage
DNA aneuploidl ofcells in
Grading Total cases(%) S phase
Grade 1 3/8 (38) 3.3
2 6/10 (60) 4.9
3 17/23 (74) 6.1
Broders' 2/4 5/8 (62) 3.0
3/4 9/15 (60) 4.8
4/4 14/18 (78) 7.1
clustered at the highest grade of histological
malignancy. Table IV shows there was a relation
between DNA index and percentage of cells in S
phase of the cell cycle. The 3.5% of cells in S found
in DNA diploid tumours is in fact significantly
lower (P<0.05) than the 14.1% in DNA aneuploid
tumours.
Discussion
In our conditions, despite efforts to concentrate
atypical cells in the cell suspension to be analyzed,
only 43% of the fluid or solid samples from
ovarian cancer patients were suitable for flow
cytometry studies on the basis of cytological
identification of atypical cells. In the 56 specimens
analyzed we demonstrated the presence of different
ratios of atypical cell populations mixed with
normal cells (Haskill et al., 1982, 1983). However,
24 specimens (43%) showed no measurable
deviations from the diploid state. This may be an
overestimate of the true frequency since our
discriminatory capacity between two cell popu-
lations is in the 2-5% range, (Friedlander et al.,
1984a). On the other hand the identification of at
least 2% of atypical cells in the suspensions to
be stained for flow cytometry studies avoids the
risk of having samples containing only normal cells,
as suggested by other authors (Friedlander et al.,
1984b).
In the 32 cases in which the DNA index was
aneuploid, no hypodiploid or hypertetraploid
tumours were detected; in all cases the DNA index
ranged from 1.2 to 2.0 (Friedlander et al., 1983;
Frankfurt et al., 1984; Atkin & Kay, 1979). This
has already been reported for other malignancies
(Baisch et al., 1982; Barlogie et al., 1978, 1980;
Diamond et al., 1982; Teodori et al., 1983;
Frankfurt et al., 1984).
Aneuploidy of ovarian tumours was characterized
by only one DNA aneuploid population of cancer
cells; our data correspond with findings on ovarian
cancer by Van-Haaften and Frankfurt (Frankfurt et
al., 1984; Van Haaften-Day et al., 1983). Other
studies (Friedlander et al., 1983; 1984a,b) report a
few cases characterized by mixed DNA aneuploid
populations.
Table IV Correlation between ploidy and percentage of cells in different cell cycle phasesa
DNA diploid tumours DNA aneuploid tumours
%G1±s.d. % S+s.d. % G2+M+s.d. % G1+s.d. % S+s.d. % G2+M+s.d.
91.7+6.2 3.5 + 4.08 5.2+ 3.03 76.6+12 14.1+10.1 9.1+4.6
(71.5-96) (0.14-16.1) (1.7-12.4) (54.7-97.2) (1.4-37.1) (1-17)
aThe number in brackets are the lowest and highest percentages of cells in the different cell cycle phases.DNA INDEX OF OVARIAN CANCERS 571
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Figure 7 DNA pattern and cell cycle distribution of ovarian cancer cells from four different samples from one
patient (no. 34) before and after in vitro culture. A = T(Oh) before seeding in culture; B-C = primary culture;
D = 1st passage in vitro.
The different DNA indices of samples from
different patients seems not to be due to instability
of the malignant genome, as no differences were
found in different samples obtained from the same
patient (Barlogie et al., 1978; 1979) even from
different sites of malignancy and at intervals of
several months. It has also been reported that after
one cell population disappears in response to
treatment, relapsing cells have the same DNA index
(Friedlander et al., 1984a).
The s'lability of the DNA index for each
individual tumour was confirmed after primary
culture and at the first passage, suggesting an
intrinsic stability of the tumour genome, at least for
some period of time; however, changes have been
reported over a period of years (Bunn et al., 1982;
Friedlander et al., 1984a).
With regard to the effects of in vitro culture on
ovarian cancer cells, the equilibrium of the cycling
population was only shifted in favour of malignant
more than normal elements (Van Haaften-Day et
al., 1983). In fact this type of tumour grows better
in culture than stromal cells. This finding, added to
our previous data showing that ovarian cancer cells
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in culture respond to anticancer agents with a
degree of inhibition comparable to the measurable
response of the patient (Morasca et al., 1983),
confirms that ovarian cancers in culture maintain
their individual features. However, since only 57%
of tumours grew in our culture conditions, the
other 43% must have metabolic needs that are not
satisfied in this in vitro environment.
Another consideration is the low proportion of
takes (9/24) in primary culture of the DNA diploid
tumours, which were almost always contaminated
by granulocytes, lymphocytes and stromal elements.
DNA aneuploid tumours were able to grow in vitro
in 24/32 cases.
When the tumour DNA index was compared
with the degree of malignancy, good agreement was
found with histological gradings, the degree of
malignancy being highest among DNA aneuploid
and growing cells. It should be noted that flow
cytometry of the DNA index gives quantitative
information on DNA while the gradings refer to
the number of malignant cells in the tissue and its
morphological appearance. No absolute link is
therefore expected between the two evaluations.
Recent papers, however, do report a correlation
between DNA index and histological grading
(Laerum & Farsund, 1981; Linden, 1982; Atkin &
Kay, 1979; Baisch et al., 1982) with which we fully
agree.
When the DNA index was correlated with the
proliferative activity of ovarian cancer cells,
measured by the proportion of cells in S phase,
DNA diploid tumours presented a relatively low
percentage of cells in S phase, 3.5%; DNA
aneuploid tumours gave a higher percentage, 14.1%.
These findings are in agreement with previous
studies (Linden, 1982; Barlogie et al., 1983;
Friedlander et al., 1983, 1984a) and could be
important for determining the biological properties
of the tumour. They could give useful information
on the choice of a chemotherapeutic regimen or as
a prognostic index. Studies are in progress to
correlate the proliferative activity of ovarian
cancers with patients' survival.
However, the static information of the
proportion of cells in S phase, collected by flow
cytometry, may assume different meanings when
cell cycles are perturbed by chemotherapeutic
agents. We feel therefore that a more precise
interpretation of % S phase can be given only after
more definitive kinetic analysis .of the phenomenon.
It thus appears that ovarian cancer constitutes a
family of tumours with well-defined stable DNA
indices, related to the degree of malignancy. The
tumour may be growing or not at the time of
sampling, and it may adapt differently to an in vitro
environment. Ovarian cancer cells have their own
sensitivity to anticancer agents as already shown in
vitro. (Morasca et al.,'l983; Von Hoff et al., 1981;
Wilson & Neal, 1981). Whether and to what extent
DNA index and growth capacity are related to
malignancy and sensitivity to therapeutic approaches
remains to be established.
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